Protalix BioTherapeutics (NYSE:PLX) Rating Increased to Buy at StockNews.com

StockNews.com upgraded shares of Protalix BioTherapeutics (NYSE:PLX) from a hold rating to a buy rating in a research note published on Monday morning.

Protalix BioTherapeutics Price Performance

PLX opened at $1.67 on Monday. The firm has a fifty day moving average price of $1.15 and a 200 day moving average price of $1.12. The stock has a market cap of $122.59 million, a P/E ratio of -13.00 and a beta of 0.67. Protalix BioTherapeutics has a 1 year low of $0.82 and a 1 year high of $1.90.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. XTX Topco Ltd acquired a new stake in Protalix BioTherapeutics in the third quarter valued at approximately $36,000. Cubist Systematic Strategies LLC purchased a new position in shares of Protalix BioTherapeutics during the second quarter worth approximately $37,000. Virtu Financial LLC purchased a new position in Protalix BioTherapeutics in the 3rd quarter valued at $44,000. AQR Capital Management LLC purchased a new position in Protalix BioTherapeutics in the 2nd quarter valued at $67,000. Finally, Ground Swell Capital LLC purchased a new stake in shares of Protalix BioTherapeutics during the 2nd quarter worth $73,000. Hedge funds and other institutional investors own 16.53% of the company’s stock.

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.